[Tyrosine kinase inhibitors--solid cancers].


Tyrosine kinase inhibitors have drawn the most attention in recent years as molecular target agents for cancer treatment. The reason for this can only be the dramatic antitumor effects shown in early clinical trials against small cell cancer and chronic myeloid leukemia by the EGFR tyrosine kinase inhibitor, ZD1839, and the BCR-Abl tyrosine kinase inhibitor… (More)


Cite this paper

@article{Nakagawa2001TyrosineKI, title={[Tyrosine kinase inhibitors--solid cancers].}, author={Kentaro Nakagawa}, journal={Gan to kagaku ryoho. Cancer & chemotherapy}, year={2001}, volume={28 5}, pages={608-13} }